KOSDAQElectrical Equipment043100

Alpha AI

₩520 0.00%2026-11-18 close
Market Cap
₩10.5B
Turnover
₩0
Volume
0 shares
Shares out.
20.1M
PER
—
PBR
0.4×
EPS
-₩367
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Alpha AI in Rehabilitation: Narrower Losses, Open Questions

Alpha AI's losses have narrowed since the court opened its rehabilitation proceedings on July 2, 2026, but the rehabilitation plan and the company's listing status remain undecided.

  1. 1

    Rehabilitation is under way. The proceedings opened on July 2, 2026, and a November 18, 2026 amended filing extended the deadline for the rehabilitation plan to January 14, 2027.

  2. 2

    On a filed basis, 2025 revenue was KRW 16.8 billion, down 37.2% year on year, and the operating loss narrowed to KRW 5.72 billion from KRW 7.46 billion in 2024.

  3. 3

    In the third quarter of 2026, revenue was KRW 3 billion and the operating loss was KRW 796 million, narrower than the KRW 1.68 billion loss in the third quarter of 2025.

  4. 4

    AI businesses were added to the articles of incorporation, but in its first-quarter 2026 report the company said it had not yet pursued them in earnest.

  5. 5

    A disclaimer of audit opinion came in April 2026, a joint task force searched the company in July 2026, and reports at that time said trading was suspended. The listing status is the central question.

02

Business structure

Alpha AI was founded in 1995 as a maker and seller of medical instruments and listed on KOSDAQ in 2000. In 2025 it changed its name to Alpha AI and newly acquired a stake in AP Holdings, which marked the start of the change in its business structure.

Its core medical unit makes biomaterial metals for spine, fracture and joint use, along with surgical instruments. The products are fitted to Korean body types, hold FDA certification and are exported overseas. Domestically the company is reported to remain among the leading shares in trauma and spine.

The company once had a healthcare unit covering heated products and home medical devices, but it has said it halted that unit's operations to focus on AI.

The articles of incorporation now list AI system development and supply, large language models, autonomous driving, humanoid robots and semiconductor design optimization solutions.

However, in its first-quarter 2026 report the company said it had not yet pursued these businesses in earnest and planned to complete them later. It is also reported to be pursuing a new real-estate related business. The largest shareholder, AI Innovation Growth Equity, holds 14.93% of common shares.

In the amended rehabilitation filing dated November 18, 2026, the CEO is recorded as the administrator of the debtor. The gap between the medical device base and the AI purposes in the articles is wide, so the business split matters when reading the results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.9B-₩1.7B−88.3%
2025Q4₩2.7B-₩3.1B−113.8%
2026Q1₩3.8B-₩1.7B−43.7%
2026Q2₩3.2B-₩1.1B−35.3%
2026Q3₩3B-₩800M−26.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩23.4B-₩6B-₩8.4B−25.9%−30.0%85.8%
2023₩26.9B-₩14.1B-₩20.2B−52.6%−110.2%178.2%
2024₩26.8B-₩7.5B-₩7.1B−27.8%−23.2%116.9%
2025₩16.8B-₩5.7B-₩6.1B−34.0%−19.8%135.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 23.4 billion in 2022 to KRW 26.9 billion in 2023, up 14.9% year on year, then fell to KRW 26.8 billion in 2024, down 0.3%, and to KRW 16.8 billion in 2025, down 37.2%.

Revenue has declined for two consecutive years from 2024 through 2025, and 2023 was the largest year in the 2022 to 2025 period while 2025 was the smallest.

The operating loss was KRW 6.05 billion in 2022, KRW 14.1 billion in 2023, KRW 7.46 billion in 2024 and KRW 5.72 billion in 2025, a loss in each of the four years from 2022 through 2025.

The loss widened in 2023 and narrowed in 2024 and 2025, with operating margins of -25.9%, -52.6%, -27.8% and -34.0% in the four years. Losses narrowed while revenue shrank, which may reflect cost restructuring, but the filed figures alone do not isolate the cause.

Net loss attributable to controlling shareholders was KRW 8.38 billion in 2022, KRW 20.2 billion in 2023, KRW 7.08 billion in 2024 and KRW 6.13 billion in 2025. Net loss including non-controlling interests was KRW 6.37 billion in 2025.

The debt ratio was 85.8% in 2022, 178.2% in 2023, 116.9% in 2024 and 135.0% in 2025, and at the end of 2025 total liabilities of KRW 41.8 billion exceeded total equity of KRW 31 billion. Operating cash flow was negative in each year from 2022 through 2025, at -KRW 9.6 billion in 2025.

Quarterly revenue rose to KRW 2.74 billion in the fourth quarter of 2025, up 43.4% from the prior quarter, and to KRW 3.84 billion in the first quarter of 2026, up 40.2%, before falling for two consecutive quarters to KRW 3.19 billion and KRW 3 billion. Third-quarter 2026 revenue was up 57.1% year on year.

The operating loss was KRW 1.68 billion in the third quarter of 2025 and KRW 3.11 billion in the fourth quarter, then narrowed to KRW 1.68 billion, KRW 1.13 billion and KRW 796 million across the first three quarters of 2026.

Losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. Net loss attributable to controlling shareholders totaled KRW 7.39 billion over the most recent four quarters.

An April 2026 filing disclosed that the auditor disclaimed its opinion on the 2025 financial statements, citing a limitation of audit scope and uncertainty about going concern, so the annual figures above should be read with that result as a premise.

05

Industry analysis

Alpha AI is classified under electrical equipment, but the business described in filings and reports is centered on surgical and medical devices. For that reason, the cycle indicators of the electrical equipment sector do not apply directly.

Demand in its core business depends on spine, trauma and joint surgery volumes, and in Korea that segment is shared among several leading suppliers.

Power equipment companies such as LS ELECTRIC, Hyosung Heavy Industries and HD Hyundai Electric are exposed to power infrastructure investment cycles, so their business structures differ too much to serve as direct comparisons.

On the AI side, a 2025 report said the government was building a policy and funding base for an AI investment program worth KRW 100 trillion aimed at making Korea a top three AI power. However, filings offer little evidence that this policy flow has translated into Alpha AI's operations.

Its share price moved after AI businesses were announced during the 2025 change of control, yet 2026 reporting says the announced investments and revenue links were not realized.

Against that backdrop, the rehabilitation process and audit outcome weigh more heavily on the company's direction than the industry environment.

06

Outlook

The AI businesses added to the articles of incorporation came with the name change approved at an extraordinary shareholders meeting in July 2025. In its first-quarter 2026 report the company said it had not yet pursued these businesses in earnest and planned to complete them later.

Whether the AI businesses reach revenue will therefore depend on how the next periodic report describes them. A new real-estate related business is also reported to be in progress, and it is discussed as a line separate from the existing medical device operations.

In the rehabilitation process, the deadline for filing the rehabilitation plan was extended to January 14, 2027 after the proceedings opened on July 2, 2026. The debt adjustments and business restructuring contained in that plan are the key variables for future financial flows.

On listing, a disclaimer of audit opinion in April 2026 created a ground for delisting, and after the company objected to the delisting decision, reports in July 2026 said trading was suspended.

The improvement period runs for ten days from the day after the statutory filing deadline for the next annual business report, so the outcome of that report will shape the timing of the listing decision.

07

Valuation

PER
—
PBR
0.4×
ROE
-25.3%
EPS
-₩367
BPS
₩1,252
Dividend per share
₩0

Because the company has posted net losses over the most recent four quarters, its price-to-earnings ratio cannot be calculated, so comparison against earnings-based multiples is difficult. The price-to-book ratio sits well below 1x, meaning the market capitalization is under the book value of total equity.

Of the total equity of KRW 31 billion at the end of 2025, the portion attributable to controlling shareholders is the same KRW 31 billion, so the equity structure is simple.

Total liabilities of KRW 41.8 billion exceed total equity, however, so how book value is adjusted in the rehabilitation process is the key question. The dividend yield is close to zero, well below the sector average.

Over the longer run, operating losses continued from 2022 through 2025, and in 2026 quarterly losses have narrowed.

A price-to-book ratio based on book equity can differ from realizable asset value under a disclaimer of audit opinion and rehabilitation proceedings, so the limits of that measure should be read alongside it. The meaning of any market capitalization comparison also depends on whether trading is suspended.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing operating losses

The operating loss was KRW 5.72 billion in 2025, narrower than KRW 7.46 billion in 2024. Operating losses narrowed for three consecutive quarters from the first quarter to the third quarter of 2026. The third-quarter 2026 loss of KRW 796 million was narrower than KRW 1.68 billion a year earlier. Whether this narrowing continues is the next point to watch.

Market position in core medical devices

The medical unit makes biomaterial metals for spine, fracture and joint use, along with surgical instruments. The products hold FDA certification and are exported. That the operating base could remain after a restructuring of finances is a positive factor.

Possible financial restructuring through rehabilitation

Rehabilitation proceedings are a statutory process for adjusting debt and reshaping the capital structure. Total equity at the end of 2025 was recorded at KRW 31 billion.

If debt adjustments and a capital restructuring follow the rehabilitation plan, the financial structure could change, which can be cited as a positive variable.

09

Bear factors

Rehabilitation and going-concern uncertainty

Rehabilitation proceedings opened on July 2, 2026, and a November 18, 2026 amended filing pushed the deadline for the rehabilitation plan to January 14, 2027. In April 2026 the auditor disclaimed its opinion, citing a limitation of audit scope and uncertainty about going concern. Until a rehabilitation plan is approved, the continuity of the business remains undetermined.

Investigation and disclosure credibility

On July 10, 2026, a joint task force against stock price manipulation searched the company's headquarters and the homes of current and former executives and the largest shareholder.

According to reports, the probe concerns allegations that false AI business announcements and market manipulation brought about KRW 20 billion-plus in improper gains, and no findings have been confirmed.

The company's first-quarter 2026 report saying the AI businesses had not yet been pursued in earnest is also a point of contention over disclosure credibility.

Financial strength and cash flow

Revenue fell 37.2% to KRW 16.8 billion in 2025. Operating cash flow was negative in each year from 2022 through 2025, at -KRW 9.6 billion in 2025. Total liabilities of KRW 41.8 billion at the end of 2025 exceeded total equity of KRW 31 billion, leaving a debt ratio of 135.0%.

10

Risk factors

Listing and trading risk

A disclaimer of audit opinion in April 2026 created a ground for delisting, and reports in July 2026 said trading was suspended after the company objected to the delisting decision. A designation notice and a deferral of the unfaithful disclosure designation were also disclosed in March 2026.

Whether the listing is maintained depends on the rehabilitation process and the outcome of the annual report filing.

Legal and investigation risk

Following the July 2026 search, the probe into alleged false disclosures and market manipulation continues, and reports say authorities are also checking whether the acquirer and former management colluded. Depending on the findings, past disclosures and fundraising methods could be re-examined. This risk can shake the premises of financial judgments independently of operating results.

Governance and use-of-funds risk

Reports said that during the change of the largest shareholder in September 2025, an investment partnership acquired the stake, and share-backed borrowing, rights offerings and convertible bond issuance followed. Whether the funds raised for AI business investment were used as disclosed is also under examination. If fund flows and management change, the business direction could be reset again.

11

What to watch next

  1. January 14, 2027

    This is the deadline for filing the rehabilitation plan. Debt adjustments and the direction of the business restructuring could become visible around this date.

  2. March 31, 2027

    This is the statutory filing deadline for the 2026 annual business report. The 2026 annual revenue and operating loss, the audit opinion and the status of the AI businesses will be shown in that report.

  3. April 2027 (within 10 days after the day following the statutory annual report deadline)

    The listing decision follows the end of the improvement period. The audit opinion in the annual report is the key variable.

  4. May 15, 2027

    This is the statutory filing deadline for the first-quarter 2027 report. Quarterly revenue and operating loss trends during the rehabilitation will be visible.

12

Overall view

Alpha AI's revenue fell to KRW 16.8 billion in 2025, and operating losses continued in each year from 2022 through 2025. Quarterly losses have narrowed, with the operating loss at KRW 796 million in the third quarter of 2026.

However, a disclaimer of audit opinion in April 2026, the opening of rehabilitation proceedings and a July 2026 search, along with reports of trading suspension, have left the continuity of the business and the listing status undetermined.

The AI businesses added to the articles were described in the first-quarter 2026 report as not yet pursued in earnest, and no revenue contribution from them appears in the filed results. The contrast between total equity of KRW 31 billion and total liabilities of KRW 41.8 billion is the core of the financial structure.

The next points to confirm are the January 14, 2027 deadline for the rehabilitation plan, the audit opinion and results in the 2026 annual report due by March 31, 2027, and the course of the investigation. The factual position of this stock depends heavily on the rehabilitation process and the listing outcome.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ibtomato.com
  2. calculator.io.kr
  3. m.news.nate.com
  4. butler.works
  5. comp.fnguide.com
  6. edaily.co.kr
  7. edaily.co.kr
  8. stockanalysis.com
  9. news.nate.com
  10. specialtimes.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. topstarnews.net
  18. m.news.nate.com

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis